We report on the cytogenetic and molecular characterization of a constitutional de novo ring chromosome 22 (r(22)) in 2 unrelated patients with emphasis on different hypotheses proposed to explain the phenotypic variability characterizing this genomic disorder. In both patients, molecular investigations using FISH and array-CGH techniques revealed a 22q terminal deletion involving the 22q13.33 critical region. The size of the deletion was estimated to at least 1.35 Mb in the first proband and to only 300 kb in the second. They both exhibited the major features of r(22) syndrome, but the first patient was more profoundly affected. He had a more severe phenotype, further complicated by behavioral anomalies, autistic-like features with abnormal EEG pattern and brain MRI profile. Haploinsufficiency of the SHANK3 gene, lying in the minimal critical region, is nowadays considered as responsible for most neurobehavioral anomalies. Nevertheless, phenotypic severity and occurrence of additional features in the first patient suggest a potential involvement of one or more specific gene(s) located proximally to SHANK3 (as PLXNB2, PANX2, ALG12 or MLC1), acting either independently of it or by regulating or promoting its expression and thus disrupting its function when deleted.

Keywords:
Array-CGH, Autistic-like features, Critical region 22q13.33, Ring 22, Speech-language delay
1.
Adham IM, Grzeschik KH, Geurts van Kessel AH, Engel W: The gene encoding the human preproacrosin (ACR) maps to the q13-qter region on chromosome 22. Hum Genet 84:59-62 (1989).
2.
Bisgaard AM, Kirchhoff M, Nielsen JE, Kibaek M, Lund A, et al: Chromosomal deletion unmasking a recessive disease: 22q13 deletion syndrome and metachromatic leukodystrophy. Clin Genet 75:175-179 (2009).
3.
Bruzzone R, Hormuzdi SG, Barbe MT, Herb A, Monyer H: Pannexins, a family of gap junction proteins expressed in brain. Proc Natl Acad Sci USA 100:13644-13649 (2003).
4.
Delahaye A, Toutain A, Aboura A, Dupont C, Tabet AC, et al: Chromosome 22q13.3 deletion syndrome with a de novo interstitial 22q13.3 cryptic deletion disrupting SHANK3. Eur J Med Genet 52:328-332 (2009).
5.
De Mas P, Chassaing N, Chaix Y, Vincent MC, Julia S, et al: Molecular characterisation of a ring chromosome 22 in a patient with severe language delay: a contribution to the refinement of the subtelomeric 22q deletion syndrome. J Med Genet 39:e17 (2002).
6.
Demirhan O, Tunç E: Phenotypic correlations in a patient with ring chromosome 22. Indian J Hum Genet 16:97-99 (2010).
7.
Denayer E, Brems H, de Cock P, Evans GD, Van Calenbergh F, et al: Pathogenesis of vestibular schwannoma in ring chromosome 22. BMC Med Genet 10:97 (2009).
8.
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, et al: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39:25-27 (2007).
9.
Evans DG, Watson C, King A, Wallace AJ, Baser ME: Multiple meningiomas: differential involvement of the NF2 gene in children and adults. J Med Genet 42:45-48 (2005).
10.
Gauthier J, Spiegelman D, Piton A, Lafrenière RG, Laurent S, et al: Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B:421-424 (2009).
11.
Gibbons B, Tan SY, Tam PY: Ring chromosome 22 resulting in partial monosomy in a mentally retarded boy. Singapore Med J 40:273-275 (1999).
12.
Giza J, Urbanski MJ, Prestori F, Bandyopadhyay B, Yam A, et al: Behavioral and cerebellar transmission deficits in mice lacking the autism-linked gene islet brain-2. J Neurosci 30:14805-14816 (2010).
13.
Grubenmann CE, Frank CG, Kjaergaard S, Berger EG, Aebi M, Hennet T: ALG12 mannosyltransferase defect in congenital disorder of glycosylation type lg. Hum Mol Genet 11:2331-2339 (2002).
14.
Hannachi H, Mougou-Zerelli S, Ben Abdallah I, Mama N, Hamdi I, et al: Clinical and molecular characterization of a combined 17p13.3 microdeletion with partial monosomy 21q21.3 in a 26-year-old man. Cytogenet Genome Res 135:102-110 (2011).
15.
Iourov IY, Vorsanova SG, Yurov YB: Chromosomal mosaicism goes global. Mol Cytogenet 1:26-32 (2008).
16.
ISCN (2009): An International System for Human Cytogenetic Nomenclature, Shaffer LG, Slovak ML, Campbell LJ (eds). Basel, Karger, 2009.
17.
Ishmael HA, Cataldi D, Begleiter ML, Pasztor LM, Dasouki MJ, et al: Five new subjects with ring chromosome 22. Clin Genet 63:410-414 (2003).
18.
Jeffries AR, Curran S, Elmslie F, Sharma A, Wenger S, et al: Molecular and phenotypic characterization of ring chromosome 22. Am J Med Genet A 137:139-147 (2005).
19.
Jobanputra V, Ash E, Anyane-Yeboa K, Warburton D, Levy B: Changes in an inherited ring (22) due to meiotic recombination? Implications for genetic counseling. Am J Med Genet A 149A:1310-1314 (2009).
20.
Koç A, Karaer K, Ergün MA, Yirmibeş-Karaoğuz M, Kan D, et al: A case with a ring chromosome 22. Turk J Pediatr 50:193-196 (2008).
21.
Lam ACF, Lai KKS, Lam STS: Distinctive phenotype in a case of ring chromosome 22 with features of 22q13.3 deletion syndrome. Paediatrics 11:317-319 (2006).
22.
Leegwater PA, Yuan BQ, van der Steen J, Mulders J, Könst AA, et al: Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts. Am J Hum Genet 68:831-838 (2001).
23.
Luciani JJ, de Mas P, Depetris D, Mignon-Ravix C, Bottani A, et al: Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. J Med Genet 40:690-696 (2003).
24.
Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, et al: Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81:1289-1297 (2007).
25.
Phelan MC: Deletion 22q13.3 syndrome. Orphanet J Rare Dis 3:14 (2008).
26.
Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, et al: 22q13 deletion syndrome. Am J Med Genet 101:91-99 (2001).
27.
Rossi E, Riegel M, Messa J, Gimelli S, Maraschio P, et al: Duplications in addition to terminal deletions are present in a proportion of ring chromosomes: clues to the mechanisms of formation. J Med Genet 45:147-154 (2008).
28.
Tommerup N, Lothe R: Constitutional ring chromosomes and tumour suppressor genes. J Med Genet 29:879-882 (1992).
29.
Tsilchorozidou T, Menko FH, Lalloo F, Kidd A, De Silva R, et al: Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J Med Genet 41:529-534 (2004).
30.
Weleber RG, Hecht F, Giblett ER: Ring-G chromosome, a new G-deletion syndrome? Am J Dis Child 115:489-493 (1968).
31.
Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, et al: Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 40:575-584 (2003).
32.
Wilson HL, Crolla JA, Walker D, Artifoni L, Dallapiccola B, et al: Interstitial 22q13 deletions: genes other than SHANK3 have major effects on cognitive and language development. Eur J Hum Genet 16:1301-1310 (2008).
33.
Worzfeld T, Püschel AW, Offermanns S, Kuner R: Plexin-B family members demonstrate non-redundant expression patterns in the developing mouse nervous system: an anatomical basis for morphogenetic effects of Sema4D during development. Eur J Neurosci 19:2622-2632 (2004).
34.
Zuccarello D, Dallapiccola B, Novelli A, Foresta C: Azoospermia in a man with a constitutional ring 22 chromosome. Eur J Med Genet 53:389-391 (2010).
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.